ESHAP--an effective chemotherapy regimen in refractory and relapsing lymphoma: a 4-year follow-up study.

@article{Velasquez1994ESHAPanEC,
  title={ESHAP--an effective chemotherapy regimen in refractory and relapsing lymphoma: a 4-year follow-up study.},
  author={W. Velasquez and P. Mclaughlin and S. Tucker and F. Hagemeister and F. Swan and M. Rodriguez and J. Romaguera and E. Rubenstein and F. Cabanillas},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={1994},
  volume={12 6},
  pages={
          1169-76
        }
}
PURPOSE This study attempted to determine the efficacy of the combination of etoposide (VP-16), methyl-prednisolone, and cytarabine (Ara-C) with or without cisplatin in relapsing and refractory adult lymphoma patients. PATIENTS AND METHODS The first 63 patients were randomized to receive VP-16 40 mg/m2/d for 4 days, methylprednisolone 500 mg intravenously daily for 5 days, and Ara-C 2 g/m2 intravenously over 2 to 3 hours on day 5 with or without cisplatin 25 mg/m2 IV administered by 24-hour… Expand

Paper Mentions

Interventional Clinical Trial
This trial proposes a therapy for pediatric Hodgkin lymphoma with the objective of achieving high levels of long lasting complete remission with less risk of late effects… Expand
ConditionsPediatric Hodgkin's Disease
InterventionDrug, Radiation
Interventional Clinical Trial
The purpose of this study is to assess whether patients who are likely to fail R-CHOP, as predicted by a mid-treatment PET scan, can have an improved outcome if switched to a standard… Expand
ConditionsAdvanced Stage Diffuse Large B-Cell Non-Hodgkin's Lymphoma, Lymphoma, Non-Hodgkin
InterventionDrug, Other
Interventional Clinical Trial
Open-labeled, multicenter, phase I/II study of imatinib combined with ESHAP as salvage therapy in relapsed/refractory non-Hodgkin's lymphoma  
ConditionsLymphoma, Non-Hodgkin
InterventionDrug
ESHAP as salvage therapy for refractory non-Hodgkin's lymphoma: Taiwan experience.
ASHAP – an effective salvage therapy for recurrent and refractory malignant lymphomas
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 24 REFERENCES
Results of MIME salvage regimen for recurrent or refractory lymphoma.
MACOP-B chemotherapy for the treatment of diffuse large-cell lymphoma.
EPOCH chemotherapy: toxicity and efficacy in relapsed and refractory non-Hodgkin's lymphoma.
  • W. Wilson, G. Bryant, +7 authors B. Cheson
  • Medicine
  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 1993
Treatment of relapsed non-Hodgkin's lymphomas with dexamethasone, high-dose cytarabine, and cisplatin before marrow transplantation.
Superiority of ProMACE-CytaBOM over ProMACE-MOPP in the treatment of advanced diffuse aggressive lymphoma: results of a prospective randomized trial.
  • D. Longo, V. Devita, +7 authors R. Fisher
  • Medicine
  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 1991
High-dose carmustine, etoposide, and cisplatin and autologous bone marrow transplantation for relapsed and refractory lymphoma.
Etoposide, ifosfamide, and methotrexate with or without bleomycin in refractory or recurrent lymphomas.
...
1
2
3
...